Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids

Emanuela Tafi, Carolina Scala, Umberto Leone Roberti Maggiore, Nicolò Bizzarri, Massimo Candiani, Pier Luigi Venturini, Simone Ferrero

Research output: Contribution to journalArticle

Abstract

Introduction: Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). SPRMs are a new class of progesterone-receptor ligands that exert tissue selective agonist, antagonist or mixed agonist-antagonist activity in target cells. UPA inhibits the proliferation, induces apoptosis of leiomyoma cells in vitro and demonstrates potent progesterone antagonist activity in vitro and in vivo.Areas covered: This manuscript aims to review the available data on safety of UPA in the treatment of uterine fibroids. Data and articles included in this manuscript were obtained via PubMed, Medline and Embase up to November 2014.Expert opinion: UPA is efficacious in the treatment of uterine fibroids before surgery; it decreases leiomyoma volume and uterine bleeding; furthermore, it improves quality of life. Short-term administration of UPA has been shown to be safe at short follow-up (months) and it is associated with minimal adverse side effects; further studies with longer follow-up are required to define the safety profile of UPA on endometrial histology.

Original languageEnglish
Pages (from-to)965-977
Number of pages13
JournalExpert Opinion on Drug Safety
Volume14
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Drug Evaluation
Leiomyoma
Safety
Progesterone Receptors
Therapeutics
Uterine Hemorrhage
Expert Testimony
PubMed
Progesterone
ulipristal acetate
Histology
Quality of Life
Apoptosis
Ligands

Keywords

  • Safety
  • Selective progesterone-receptor modulators
  • Tolerability
  • Treatment
  • Ulipristal acetate
  • Uterine fibroids

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. / Tafi, Emanuela; Scala, Carolina; Maggiore, Umberto Leone Roberti; Bizzarri, Nicolò; Candiani, Massimo; Venturini, Pier Luigi; Ferrero, Simone.

In: Expert Opinion on Drug Safety, Vol. 14, No. 6, 01.06.2015, p. 965-977.

Research output: Contribution to journalArticle

Tafi, Emanuela ; Scala, Carolina ; Maggiore, Umberto Leone Roberti ; Bizzarri, Nicolò ; Candiani, Massimo ; Venturini, Pier Luigi ; Ferrero, Simone. / Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. In: Expert Opinion on Drug Safety. 2015 ; Vol. 14, No. 6. pp. 965-977.
@article{ad96ebc47f904729abf31755cfaeb56a,
title = "Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids",
abstract = "Introduction: Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). SPRMs are a new class of progesterone-receptor ligands that exert tissue selective agonist, antagonist or mixed agonist-antagonist activity in target cells. UPA inhibits the proliferation, induces apoptosis of leiomyoma cells in vitro and demonstrates potent progesterone antagonist activity in vitro and in vivo.Areas covered: This manuscript aims to review the available data on safety of UPA in the treatment of uterine fibroids. Data and articles included in this manuscript were obtained via PubMed, Medline and Embase up to November 2014.Expert opinion: UPA is efficacious in the treatment of uterine fibroids before surgery; it decreases leiomyoma volume and uterine bleeding; furthermore, it improves quality of life. Short-term administration of UPA has been shown to be safe at short follow-up (months) and it is associated with minimal adverse side effects; further studies with longer follow-up are required to define the safety profile of UPA on endometrial histology.",
keywords = "Safety, Selective progesterone-receptor modulators, Tolerability, Treatment, Ulipristal acetate, Uterine fibroids",
author = "Emanuela Tafi and Carolina Scala and Maggiore, {Umberto Leone Roberti} and Nicol{\`o} Bizzarri and Massimo Candiani and Venturini, {Pier Luigi} and Simone Ferrero",
year = "2015",
month = "6",
day = "1",
doi = "10.1517/14740338.2015.1021773",
language = "English",
volume = "14",
pages = "965--977",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids

AU - Tafi, Emanuela

AU - Scala, Carolina

AU - Maggiore, Umberto Leone Roberti

AU - Bizzarri, Nicolò

AU - Candiani, Massimo

AU - Venturini, Pier Luigi

AU - Ferrero, Simone

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Introduction: Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). SPRMs are a new class of progesterone-receptor ligands that exert tissue selective agonist, antagonist or mixed agonist-antagonist activity in target cells. UPA inhibits the proliferation, induces apoptosis of leiomyoma cells in vitro and demonstrates potent progesterone antagonist activity in vitro and in vivo.Areas covered: This manuscript aims to review the available data on safety of UPA in the treatment of uterine fibroids. Data and articles included in this manuscript were obtained via PubMed, Medline and Embase up to November 2014.Expert opinion: UPA is efficacious in the treatment of uterine fibroids before surgery; it decreases leiomyoma volume and uterine bleeding; furthermore, it improves quality of life. Short-term administration of UPA has been shown to be safe at short follow-up (months) and it is associated with minimal adverse side effects; further studies with longer follow-up are required to define the safety profile of UPA on endometrial histology.

AB - Introduction: Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). SPRMs are a new class of progesterone-receptor ligands that exert tissue selective agonist, antagonist or mixed agonist-antagonist activity in target cells. UPA inhibits the proliferation, induces apoptosis of leiomyoma cells in vitro and demonstrates potent progesterone antagonist activity in vitro and in vivo.Areas covered: This manuscript aims to review the available data on safety of UPA in the treatment of uterine fibroids. Data and articles included in this manuscript were obtained via PubMed, Medline and Embase up to November 2014.Expert opinion: UPA is efficacious in the treatment of uterine fibroids before surgery; it decreases leiomyoma volume and uterine bleeding; furthermore, it improves quality of life. Short-term administration of UPA has been shown to be safe at short follow-up (months) and it is associated with minimal adverse side effects; further studies with longer follow-up are required to define the safety profile of UPA on endometrial histology.

KW - Safety

KW - Selective progesterone-receptor modulators

KW - Tolerability

KW - Treatment

KW - Ulipristal acetate

KW - Uterine fibroids

UR - http://www.scopus.com/inward/record.url?scp=84929577580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929577580&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.1021773

DO - 10.1517/14740338.2015.1021773

M3 - Article

C2 - 25772793

AN - SCOPUS:84929577580

VL - 14

SP - 965

EP - 977

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -